The economic case for new stroke thrombolytics

Stroke

Volumn 41, Issue 10 SUPPL. 1, 2010, Pages

  Johnston, S Claiborne ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cost effectiveness; health care; public health; quality adjusted life year; thrombolysis

Indexed keywords

FIBRINOLYTIC AGENT; GENERIC DRUG; NEW DRUG; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG RESEARCH; ECONOMIC ASPECT; FIBRINOLYTIC THERAPY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SOCIETY; STROKE; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; FIBRINOLYTIC AGENTS; HUMANS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; STROKE; THROMBOLYTIC THERAPY; UNITED STATES;

EID: 77957993083     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.597351     Document Type: Conference Paper

References (19)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG, Walker MD. Cost-effectiveness of tissue plasminogen activator for acute ische-mic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50: 883-890.
3. Mar J, Begiristain JM, Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis. 2005;20: 193-200.
4. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, Lewis S, Lindley R, Neilson A, Wardlaw J. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke. 2004;35: 1490-1497.
5. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996
6. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
7. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332: 1418-1424.
8. Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet. 2006;367:1319-1327.
9. Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York, NY: Oxford University Press; 1994.
10. Search strategies for MEDLINE in Ovid Syntax and the PubMed translation. Health Information Research Unit, McMaster University. Available at: http://hiru.mcmaster.ca/hedges/. Accessed November 8, 2005.
11. California Acute Stroke Pilot Registry Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology. 2005;64:654-659.
12. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359: 1317-1329.
13. American Heart Association. Heart Disease and Stroke Statistics -2004 Update. Dallas, Tex: American Heart Association; 2004.
14. Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, Hicken-bottom S, Karp H, LaBresh KA, Malarcher A, Mensah G, Moomaw CJ, Schwamm L, Weiss P. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke. 2005;36:1232-1240.
15. Comparative real Gross Domestic Product per capita and per employed person, fifteen countries, 1960 -2004 (page 9). 2005:1-15
16. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. Osteoporos Int. 1998;8 (Suppl 4):S7-S80.
17. Bureau of Labor Statistics Data: Prices and Living Conditions. U.S. Department of Labor Web site. Available at: http://www.bls.gov/data/. Accessed September 6, 2005.
18. Adams CP, Brantner VV. Spending on new drug development. Health Econ. 2008;19:130-141.
19. Silverman E. Which drugs have the biggest pre-tax margins? Available at http://www.pharmalot.com/2010/01/which-drugs-have-the-biggest-pre-tax-margins/. Accessed July 6, 2010.